Pelthos Therapeutics Inc. (PTHS)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $29.24M
Last updated: Nov 17, 2026 at 11:04 AM ET
Pelthos Therapeutics Inc. (PTHS) Stock Forecast
Analysts expect Pelthos Therapeutics (PTHS) to earn -$18.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $59.62M. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 71.0%.
- Fiscal year ending Dec 31, 2026
- -$18.02
- EPS consensus, revenue $59.62M
- Fiscal year ending Dec 31, 2027
- -$5.37
- EPS consensus, revenue $101.93M
- Next report
- Mar 17, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$18.02 | -$27.45 to -$12.40 | 3 | $59.62M | $52.16M to $72.10M | 7 |
| Dec 31, 2027 | -$5.37 | -$7.76 to -$1.45 | 3 | $101.93M | $62.58M to $138.60M | 7 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.83 | -$4.62 to -$1.25 | 9 | $17.53M | $13.16M to $26.25M | 9 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$10.66.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$18.02 | -$17.87 | -$18.82 | -$18.82 | -$10.66 | N/A |
| Fiscal year ending Dec 31, 2027 | -$5.37 | -$5.14 | -$5.68 | -$5.68 | -$2.13 | N/A |
Frequently Asked Questions About PTHS
What is the PTHS stock forecast?
Consensus analyst estimates put Pelthos Therapeutics's EPS at -$18.02 for the fiscal year ending Dec 31, 2026, on revenue of $59.62M. The consensus rating from 7 analysts is Buy.
How do analysts rate PTHS stock?
Of 7 analysts covering Pelthos Therapeutics, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PTHS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$18.02, with estimates from -$27.45 to -$12.40 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.37, with estimates from -$7.76 to -$1.45 from 3 analysts.
What revenue do analysts expect from Pelthos Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $59.62M, with estimates from $52.16M to $72.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $101.93M, with estimates from $62.58M to $138.60M.
How many analysts cover PTHS?
7 analysts rate Pelthos Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PTHS pages: Overview, Earnings, Forecast, Financials, Competitors